doi: 10.3389/fphar.2024.1414268 Received 08 April 2024 Accepted 13 May 2024 Published 03 June 2024 Volume 15 - 2024 Edited by Sheyu Li, Sichuan University, China Reviewed by Yiyuan Gao, Sichuan University, China Heyue Du, TidalHealth Neurosurgery, United States Erin St
The Metabolic Patient: It is FDA-approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher with a comorbidity like hypertension or high cholesterol
Semaglutide is also being tested in trials against diabetic eye diseases expected to end in 2027 (NCT03811561
Certain predispositions may correlate with faster appetite rebound and earlier weight regain, making continuous therapy or alternative strategies worth considering with your provider
At a basic level, GLP-1 receptor agonists work in two well-established ways: They slow gastric emptying, and they act on the brains appetite-regulation centers to reduce food intake
Schedule an appointment with a MEDvidi provider today to determine whether semaglutide or another medication is right for you to help with weight loss and management